136 related articles for article (PubMed ID: 26892152)
1. Metastatic HER2-Positive Breast Cancer: Tailoring Treatment Un-'TIL' We Get It Right..
Jankowitz RC; Rastogi P
Oncology (Williston Park); 2016 Feb; 30(2):156, 158-9. PubMed ID: 26892152
[No Abstract] [Full Text] [Related]
2. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?
Santa-Maria CA; Nye L; Mutonga MB; Jain S; Gradishar WJ
Oncology (Williston Park); 2016 Feb; 30(2):148-55. PubMed ID: 26892151
[TBL] [Abstract][Full Text] [Related]
3. The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin?
Loibl S
JAMA Oncol; 2015 Jul; 1(4):455-6. PubMed ID: 26181253
[No Abstract] [Full Text] [Related]
4. The Evolving Landscape of HER2 Targeting in Breast Cancer.
Moasser MM; Krop IE
JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for Predicting Response to Anti-HER2 Agents.
Varadan V; Sandoval M; Harris LN
Adv Exp Med Biol; 2016; 882():155-67. PubMed ID: 26987534
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
7. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.
Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA
Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189
[TBL] [Abstract][Full Text] [Related]
8. HER2 testing in gastric cancer: An update.
Abrahao-Machado LF; Scapulatempo-Neto C
World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
[TBL] [Abstract][Full Text] [Related]
9. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
[TBL] [Abstract][Full Text] [Related]
10. Dual HER2 targeting for early breast cancer.
Johnston SR
Lancet Oncol; 2013 Nov; 14(12):1145-6. PubMed ID: 24095298
[No Abstract] [Full Text] [Related]
11. Better treatments needed for breast cancer brain metastases.
Lin NU
Lancet Oncol; 2015 Dec; 16(16):1583-4. PubMed ID: 26596673
[No Abstract] [Full Text] [Related]
12. [Novel target therapies used in breast cancer management].
Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
[No Abstract] [Full Text] [Related]
13. Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.
Di Modica M; Tagliabue E; Triulzi T
Dis Markers; 2017; 2017():7849108. PubMed ID: 29403144
[TBL] [Abstract][Full Text] [Related]
14. Current and future anti-HER2 therapy in breast cancer.
Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
[TBL] [Abstract][Full Text] [Related]
15. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
16. How can we optimize treatment of HER2-positive metastatic breast cancer?
Hamilton EP; Blackwell KL
Oncology (Williston Park); 2013 Mar; 27(3):180, 182. PubMed ID: 23687786
[No Abstract] [Full Text] [Related]
17. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
18. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
19. Targeting alternative pathways in HER2-positive breast cancer.
Rastogi P
Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739
[No Abstract] [Full Text] [Related]
20. Targeted treatments for breast cancer: a step forward.
Bachelot T; Tredan O
Lancet Oncol; 2013 May; 14(6):438-9. PubMed ID: 23602602
[No Abstract] [Full Text] [Related]
[Next] [New Search]
